Sapient

“I liken #biomarker discovery to astronomy. With the naked eye you can only see so many stars, so if you’re just looking up at the night sky, those are the stars you record and follow every day. But with a very powerful telescope, now you can see thousands upon billions of additional stars. And so your ability to understand and catalog the night sky is so much greater… and biomarkers are no different. Our technologies are the telescope to help us find more useful biomarkers. They enable us to measure thousands upon thousands more molecules in humans than we could just several years ago. And so that becomes transformative for not only the practice of medicine, but also for drug development.” Sapient’s Mo Jain, MD PhD Jain was a recent guest on ?????? ???????????? ???? ???????????? #podcast and spoke with host Samir Gondalia about advances in biomarker discovery, which enable broader and deeper probing of human biology, and how these innovations are accelerating development of precision-guided therapeutics. Listen to full conversation here: https://lnkd.in/eWMVnzCp or search "The Future of Pharma" on your favorite podcast platform! #biomarkers #biomarkerdiscovery #futureofpharma #precisionmedicine

My guest in this episode is Dr. Mo Jain, MD PhD, founder and CSO of Sapient. Dr. Mohit Jain is a physician-scientist with more than 20 years of expertise in physiology, computational biology, and mass spectrometry-based bioanalytics. He formed the Jain Laboratory at UCSD, where he led his team to develop next-generation mass spectrometry systems to probe the non-genetic landscape of disease across large-scale human studies. He founded Sapient in 2021 as a spinout of the Jain Laboratory to expand upon this mission, providing bespoke services multi-omics biomarker discovery. In this wide ranging yet focused interview, we discuss? - Biomarkers and how their role has changed - The predictor for a clinical trial success - Precision guided medicine - The change in disease classification over last 20 years - Genetic vs non-genetic reasons for disease - Next generation mass spectrometry and - Different disease expression in different people I enjoyed my chat with Dr. Jain, particularly his ability to simplify complex problems the pharma industry is facing and what should be done about it. Hope you do too. The episode link is in comments. Thanks Carla Nieser for connecting Mo and me. ISPE Boston Area Chapter

Join us on April 2 for a live #webinar exploring why 2025 is the year of plasma #proteomics. We'll deep dive into the technological advancements now enabling robust analyses of #proteins in plasma and share examples of how this data is contributing to the advancement of target identification and precision medicine strategies. Be sure to register to save your spot! https://lnkd.in/g9RqvMdf

Why is it time to rethink #massspectrometry's role in clinical protein assays? This #whitepaper explores advancements that have occurred in mass spectrometry-based proteomics, in comparison to #ELISA-based assays, that are mitigating analytical trade-offs to deliver the depth, sensitivity, and reproducibility required for protein measures that inform clinical decision-making. See the instrumentation and enrichment techniques that are enabling next-gen mass spectrometry to exceed the sensitivity and #specificity of ELISA, the current gold standard for clinical protein assays. https://lnkd.in/gjiFY-qD

We're looking forward to heading back to Boston for the #NextGenOmics conference! If you're attending or would like to meet with our team while we're in town, please reach out to Sean Ramsey and Mo Jain, MD PhD! You can also: ?? Join our scientific session on March 27: https://lnkd.in/eJtEhuCQ ?? Visit us at Booth #15 during the conference: https://lnkd.in/g8EF2Ecd

What drives a founder forward every day? Find out with my new podcast series... Code, Cells and the Golden State. First episode dropping with Mo Jain, MD PhD from Sapient dropping soon. Having not solved disease is unacceptable as a human race. Metric Bio | Metric

Wow! Thank you to everyone who attended our ???????????????? ???????? ???????? talk today at #NextGenBiomed, where we discussed advances in #multiomics that are propelling next-gen #cancer therapeutics. If you missed the session or have follow-up questions, be sure to stop by our Booth, 78, to connect with Mo Jain, MD PhD and Sean Ramsey! You can also search us on the Grip app to schedule a time to meet with them 1-on-1 during the conference. NextGen Biomed by Oxford Global #NGB2025 #NextGenBiomed2025

For years, the complexity of the human plasma proteome has been a challenge, limiting its full potential. But new innovations are changing the game. Join us for an exclusive Sapient webinar with Mo Jain, MD, PhD, and Jeramie Watrous, PhD, as we explore groundbreaking advancements in plasma proteomics - transforming biomarker discovery, drug development, and precision medicine like never before! In this session, we’ll dive into: ?? The key limitations that have held plasma proteomics back – and how we’re overcoming them ?? Cutting-edge technologies revolutionizing large-scale plasma protein analysis ?? How deep proteome insights are driving target identification & precision medicine breakthroughs If you're in drug development, biomarker research, or precision medicine, this is a must-attend event to stay ahead in 2025! ?? Wednesday 2nd April | 4 pm BST (10 am ET) Register here: https://hubs.la/Q039bqvJ0 ?????? ?????????????????? ???? ?????? ?????????????????? ????????? ???? ??????????????—????’???? ???????? ?????? ?????? ????-???????????? ??????????????????! #Bioprocessing #SupplyChainResilience #GeneTherapy #Chromatography #PlasmaProteomics #Biomarkers #DrugDiscovery #PrecisionMedicine #ProteomicsInnovation

Our ???????????? ?????????????? ???????????? offer an in-depth and non-invasive approach to measure biological activity, drug targets, and drug response over time across more than 6,000 protein groups in saliva. This includes measure of >800 known and emerging drug targets, supporting evaluation of key pharmacokinetic (PK) and pharmacodynamic (PD) metrics in a non-invasive, conveniently collected sample type that can be used in decentralized #clinical trials. From single-plex assays to comprehensive panels, you can select for your key proteins of interest among our full saliva protein assay menu. Request here: https://lnkd.in/gikFnnP6 #salivaassay #proteinassays #DCT

#ICYMI: International Women's Day was March 8, and we took the opportunity to spotlight some of the talented women on the #SapientTeam who are driving new discoveries, leading with purpose, and making an impact in science and health every day. We've compiled their shared stories below!: ? Carla Nieser, Head of Marketing: https://lnkd.in/dF5vucPR ? Priscilla Cuevas, Research Scientist I: https://lnkd.in/dm68uj3v ? Tao Long, Co-Founder and Head of Data Science: https://lnkd.in/d5gNQyDb ? Saumya Tiwari, Co-Founder and Head of Computational R&D Operations: https://lnkd.in/dfSa8BVS #InternationalWomensDay #WomensDay